GB268 alone or with other drugs for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called GB268, either alone or with other medicines, for people with advanced breast cancer. It may help by targeting cancer cells in a new way, and the study will check if it shrinks tumors or slows the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a type of breast cancer called triple-negative (TNBC) or HR+/HER2- that has spread or cannot be removed with surgery.
- You have not had certain prior treatments — the exact rules depend on which group (cohort) you join.
- You have at least one tumor that can be measured on a scan.
- You have not received an immune checkpoint inhibitor before (except in early-stage treatment, if relapse was more than 12 months ago).
- You need to provide a tissue sample (from a previous biopsy) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GB268, which is designed to help your immune system fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
Hear when a new Breast Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.